Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
2.
Transplant Proc ; 44(9): 2645-8, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23146482

RESUMO

BACKGROUND: The indoleamine, 2-3 dioxygenase (IDO) is an inducible intracellular enzyme with immunosuppressive effects mainly on lymphocyte populations. It has been postulated that indirect determination of IDO serum activity may be a marker of renal graft rejection, but its potential usefulness in heart transplantation (HT) is unknown. METHODS: This longitudinal study included 98 HT patients (83% males) who survived ≥1 year. Mean age was 54.14 ± 11.57 years. Serum IDO activity was analyzed one month after HT by means of high performance liquid chromatography and correlated with the cumulative incidence of acute rejection (AR) during one-year follow-up. AR was defined as biopsy-proven ≥ ISHLT grade 2R rejection or empirically treated non-biopsy-proven rejection. The study sample was divided into two groups: AR group (n = 51), including patients who experienced at least one AR episode during the first year after HT; No-AR group (N = 47), including the remaining patients. RESULTS: Mean serum IDO activity one month after HT was significantly higher (P = .021) in the AR group (3.32 ± 1.56) than in the no-AR group (2.62 ± 1.35). No significant association between serum IDO activity and gender (male: 3.1 ± 1.56, women: 2.43 ± 0.99, P = .092), recipient age (r = -.07, P = .943) or donor age (r = 0.108, P = 0.293) was observed. By means of binary logistic regression, an odds ratio of 1.4 [CI 95%: 1.033-1.876, P = .03] per unit increase of act-IDO was estimated, with no significant modification upon forced adjustment for age and sex. Mean glomerular filtration rate 1 month after HT was 67.01 ± 28.51 mL/min/m(2). No significant correlation between this parameter and serum IDO activity was observed (r = .160, P = .117). CONCLUSIONS: Our study suggests that serum IDO activity one month after HT might be associated with a higher risk of AR during one-year follow-up. This association seems to be independent of recipient gender, age or renal function.


Assuntos
Rejeição de Enxerto/enzimologia , Sobrevivência de Enxerto , Transplante de Coração/imunologia , Indolamina-Pirrol 2,3,-Dioxigenase/sangue , Adulto , Idoso , Biomarcadores/sangue , Cromatografia Líquida de Alta Pressão , Feminino , Taxa de Filtração Glomerular , Rejeição de Enxerto/sangue , Rejeição de Enxerto/epidemiologia , Rejeição de Enxerto/imunologia , Transplante de Coração/efeitos adversos , Humanos , Incidência , Modelos Logísticos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Razão de Chances , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Espanha/epidemiologia , Fatores de Tempo , Resultado do Tratamento , Regulação para Cima
8.
Cir. plást. ibero-latinoam ; 35(1): 73-78, ene.-mar. 2009. ilus
Artigo em Espanhol | IBECS | ID: ibc-80048

RESUMO

El siringoma condroide maligno es un tumor muy infrecuente de origen epitelial. Presentamos el caso de una mujer de 68 años con una tumoración en su brazo izquierdo, sin invasión ósea local, pero con afectación metastásica pulmonar. El diagnóstico fue de siringoma condroide maligno. Analizamos el caso, infrecuente por el tamaño del tumor y por su evolución y hacemos una revisión bibliográfica sobre el tema (AU)


Malignant chondroid siringoma is a rare tumour with epithelial ethilogy. We present a clinical case: a68 years old woman with a tumour on her left arm, without local bone invasion but with metastatic injury. Diagnosis was, malignant chondroid syringoma. We present this case because of its size and evolution and a review of literature (AU)


Assuntos
Humanos , Feminino , Idoso , Neoplasias de Tecidos Moles/diagnóstico , Neoplasias de Tecidos Moles/cirurgia , Adenoma Pleomorfo/diagnóstico , Adenoma Pleomorfo/cirurgia , Neoplasias de Tecidos Moles/patologia , Neoplasias Pulmonares/secundário
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...